|Bid||135.50 x 800|
|Ask||138.89 x 800|
|Day's Range||134.54 - 137.22|
|52 Week Range||87.49 - 236.17|
|Beta (3Y Monthly)||2.71|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 19, 2019 - Feb 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||179.39|
NEW YORK, Feb. 14, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie (ABBV) enters a global strategic transaction agreement with privately-held Teneobio to develop and commercialize the latter's pre-clinical immunotherapy candidate, TNB-383B, as a multiple myeloma treatment.
Mr. Baird joins bluebird from Amicus Therapeutics, Inc., where he was the CFO for the past seven years and brings a demonstrated track record of successfully leading companies in all phases of discovery, development and commercialization. Jeff Walsh, who has held various roles over the last eight years at bluebird bio — including chief operating officer and, most recently, chief financial and strategy officer — will assume the new dedicated role of chief strategy officer to drive corporate development and the company’s overall growth strategy.
bluebird bio Inc NASDAQ/NGS:BLUEView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is high for BLUE with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting BLUE. However, the last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding BLUE totaled $7.82 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Ahead of the opening this week, the German biotech firm signed two major partnerships with Boston-based Orchard Therapeutics and San Francisco-based Denali Therapeutics, and is also in the process of closing another partnership with a U.S. biotech company focused on hemophilia treatments.
NEW YORK, NY / ACCESSWIRE / January 31, 2019 / U.S. equities regained footing on Wednesday as investors cheered the latest round of corporate earnings and the Federal Reserve kept the interest rates unchanged ...
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that there are more than a few examples Read More...
The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of bluebird bio, Inc. (“bluebird bio” or “the Company”) (NASDAQ: BLUE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. On December 1, 2018, bluebird bio disclosed to the market that the Company had “announced new long-term data from the completed Phase 1/2 Northstar (HGB-204) study of investigational LentiGlobin™ gene therapy in patients with transfusion-dependent β-thalassemia (TDT) and from the ongoing Phase 1/2 HGB-206 study of LentiGlobin in patients with sickle cell disease (SCD) today at the 60th Annual Meeting of the American Society of Hematology (ASH).” An article posted on December 3, 2018, to Seeking Alpha commented on the announcement, asserting “results were lower than initial data reported a year ago indicating a lower rate of production of anti-sickling hemoglobin.” Based on this news, shares of bluebird bio fell more than 5% on the same day.
NEW YORK, NY / ACCESSWIRE / January 11, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers bluebird bio, Inc.("bluebird" or the ''Company") ...
NEW YORK, NY / ACCESSWIRE / January 11, 2019 / U.S. markets finished in the green on Thursday, however gains were held back by a sharp decline in Macy’s shares that pressured retail stocks lower. The Dow ...
Bristol-Myers Squibb (BMY) last week ponied up $74 billion, a 54% premium, for biotechnology heavyweight Celgene. Big Pharma needs the next generation of treatments to fuel future growth. Another massive purchase was IBM’s (IBM) $33 billion takeover of software firm Red Hat Inc. (RHT) The fact that Big Blue paid a premium of more than 60% in October, one of the worst months for stocks in recent memory, is proof that mega-cap technology companies aren’t afraid to shell out big bucks even amid talk of a tough stock market.
A Boston-area biotech says it may have a found a way to handle the expected seven-figure cost of its experimental gene therapy: paying on installment. Bluebird Bio Inc. is developing plans to sell its first gene-replacement therapy, for a rare inherited blood disease, on a five-year installment plan, with each annual payment contingent on its treatment’s continued effectiveness. “Whether it’s just below or considerably below [$2.1 million] is something we need to sort through,” Mr. Leschly said.
“Access to the Inhibrx sdAb binder technology will allow us to combine the advancements we’ve made with our T cell therapy platform with their sdAb binder technology to generate novel cellular therapies with the potential to help patients in their fight against cancer,” said Philip Gregory, D. Phil., chief scientific officer, bluebird bio. “We are pleased to have formalized our relationship with bluebird bio, allowing us to couple our proprietary sdAb platform with a leading cell therapy platform,” said Brendan Eckelman, Chief Scientific Officer and Executive Vice President of Corporate Strategy of Inhibrx.